Aandelen in “Farmaceutische Producten: Generisch”

Aandeel Datum Koers Evolutie
vlag BridgeBio Pharma Inc 3/03 64,530 USD
-1,48% 		-1,48%

Nieuws over “Farmaceutische Producten: Generisch”

3/03 · Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug · Persbericht

3/03 · Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug · Persbericht

24/02 · Teva to Present at the Upcoming Investor Conferences in March · Persbericht

20/02 · U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

17/02 · Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease · Persbericht

28/01 · Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential · Persbericht

27/01 · Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ · Persbericht

14/01 · AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine · Persbericht

12/01 · Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation · Persbericht

11/01 · Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo · Persbericht

5/01 · Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

24/12 · S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive · Persbericht

19/12 · Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® · Persbericht

12/12 · Teva Releases Q4 2025 Aide Memoire · Persbericht

12/12 · Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 · Persbericht

9/12 · Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults · Persbericht

8/12 · Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US · Persbericht

Mijn selecties